IRIS/Inhalation unit risks

This page is a knowledge crystal of subtype variable. The page identifier is Op_en5777
Moderator:Kristiina (see all)
Upload data Show results

Question

What are the Inhalation unit risks according to the IRIS database?

Answer

Inhalation unit risks

IRIS/Inhalation unit risks(per µg /m

Obs	Substance	CASRN	Precursor Effect/ Tumor Type	Extrapolation Method	Unit	Inhalation unit risks	Study Route	IRIS identifier
1	Acenaphthene	83-32-9	Not Assessed under the IRIS program.
2	Acenaphthylene	208-96-8	Not Assessed under the IRIS program.
3	Acephate	30560-19-1	Not Assessed under the IRIS program.
4	Acetaldehyde	75-07-0	Nasal squamous cell carcinoma or adenocarcinoma	Linearized multistage-variable exposure input form (extra risk)	per µg/m3	2.2x10-6	Inhalation
5	Acetochlor	34256-82-1	Not Assessed under the IRIS program.
6	Acetone	67-64-1	Not Assessed under the IRIS program.
7	Acetonitrile	75-05-8	Not Assessed under the IRIS program.
8	Acetophenone	98-86-2	Not Assessed under the IRIS program.
9	Acetyl chloride	75-36-5	Not Assessed under the IRIS program.
10	Acifluorfen, sodium	62476-59-9	Not Assessed under the IRIS program.
11	Acrolein	107-02-8	Not Assessed under the IRIS program.
12	Acrylamide	79-06-1	thyroid tumors and tunica vaginalis mesotheliomas	Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.	per µg /m3	1x10-4	Oral, drinking water
13	Acrylic acid	79-10-7	Not Assessed under the IRIS program.
14	Acrylonitrile	107-13-1	Respiratory cancer	Average relative risk	per µg /m3	6.8x10-5	Inhalation
15	Adiponitrile	111-69-3	Not Assessed under the IRIS program.
16	Alachlor	15972-60-8	Not Assessed under the IRIS program.
17	Alar	1596-84-5	Not Assessed under the IRIS program.
18	Aldicarb	116-06-3	Not Assessed under the IRIS program.
19	Aldicarb sulfone	1646-88-4	Not Assessed under the IRIS program.
20	Aldrin	309-00-2	Liver carcinoma	Linearized multistage procedure, extra risk	per µg /m3	4.9x10-3	Oral, Diet
21	Ally	74223-64-6	Not Assessed under the IRIS program.
22	Allyl alcohol	107-18-6	Not Assessed under the IRIS program.
23	Allyl chloride	107-05-1	Not Assessed under the IRIS program.
24	Aluminum phosphide	20859-73-8	Not Assessed under the IRIS program.
25	Amdro	67485-29-4	Not Assessed under the IRIS program.
26	Ametryn	834-12-8	Not Assessed under the IRIS program.
27	4-Aminopyridine	504-24-5	Not Assessed under the IRIS program.
28	Amitraz	33089-61-1	Not Assessed under the IRIS program.
29	Ammonia	7664-41-7	Not Assessed under the IRIS program.
30	Ammonium acetate	631-61-8	Not Assessed under the IRIS program.
31	Ammonium methacrylate	16325-47-6	Not Assessed under the IRIS program.
32	Ammonium sulfamate	7773-06-0	Not Assessed under the IRIS program.
33	Aniline	62-53-3	Not Assessed under the IRIS program.
34	ortho-Anisidine	90-04-0	Not Assessed under the IRIS program.
35	Anthracene	120-12-7	Not Assessed under the IRIS program.
36	Antimony	7440-36-0	Not Assessed under the IRIS program.
37	Antimony trioxide	1309-64-4	Not Assessed under the IRIS program.
38	Apollo	74115-24-5	Not Assessed under the IRIS program.
39	Aramite	140-57-8	Neoplastic liver nodules and carcinomas	Linearized multistage procedure, extra risk	per µg/m3	7.1x10-6	Oral, Diet
40	Aroclor 1016	12674-11-2	Not Assessed under the IRIS program.
41	Aroclor 1248	12672-29-6	Not Assessed under the IRIS program.
42	Aroclor 1254	11097-69-1	Not Assessed under the IRIS program.
43	Arsenic, inorganic	7440-38-2	Lung cancer	Absolute-risk linear model	per µg/m3	4.3x10-3	Inhalation, Occupational exposure
44	Arsine	7784-42-1	Not Assessed under the IRIS program.
45	Asbestos	1332-21-4	Lung cancer and mesothelioma	Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma	per f/mL	2.3x10-1	Inhalation, Occupational exposure
46	Assure	76578-14-8	Not Assessed under the IRIS program.
47	Asulam	3337-71-1	Not Assessed under the IRIS program.
48	Atrazine	1912-24-9	Not Assessed under the IRIS program.
49	Avermectin B1	65195-55-3	Not Assessed under the IRIS program.
50	Azobenzene	103-33-3	Abdominal cavity sarcomas	Linearized multistage procedure, extra risk	per µg /m3	3.1x10-5	Oral, Diet
51	Barium and Compounds	7440-39-3	Not Assessed under the IRIS program.
52	Barium cyanide	542-62-1	Not Assessed under the IRIS program.
53	Baygon	114-26-1	Not Assessed under the IRIS program.
54	Bayleton	43121-43-3	Not Assessed under the IRIS program.
55	Baythroid	68359-37-5	Not Assessed under the IRIS program.
56	Benefin	1861-40-1	Not Assessed under the IRIS program.
57	Benomyl	17804-35-2	Not Assessed under the IRIS program.
58	Bentazon (Basagran)	25057-89-0	Not Assessed under the IRIS program.
59	Benz[a]anthracene	56-55-3	Not Assessed under the IRIS program.
60	Benzaldehyde	100-52-7	Not Assessed under the IRIS program.
61	Benzene	71-43-2	Leukemia	Low-dose linearity utilizing maximum likelihood estimates	per µg /m3	2.2x10-6	Inhalation
62	Benzene	71-43-2	Leukemia	Low-dose linearity utilizing maximum likelihood estimates	per µg /m3	7.8x10-6	Inhalation
63	Benzidine	92-87-5	Bladder tumors	One-hit with time factor, extra risk	per µg /m3	6.7x10-2	Inhalation, Occupational exposure
64	Benzo[a]pyrene (BaP)	50-32-8	Not Assessed under the IRIS program.
65	Benzo[b]fluoranthene	205-99-2	Not Assessed under the IRIS program.
66	Benzo[g,h,i]perylene	191-24-2	Not Assessed under the IRIS program.
67	Benzo[k]fluoranthene	207-08-9	Not Assessed under the IRIS program.
68	Benzoic acid	65-85-0	Not Assessed under the IRIS program.
69	Benzotrichloride	98-07-7	Not Assessed under the IRIS program.
70	Benzyl chloride	100-44-7	Not Assessed under the IRIS program.
71	Beryllium and compounds	7440-41-7	Lung cancer	Relative risk	per µg /m3	2.4x10-3	Inhalation, Occupational exposure
72	Bidrin	141-66-2	Not Assessed under the IRIS program.
73	Biphenthrin	82657-04-3	Not Assessed under the IRIS program.
74	1,1-Biphenyl	92-52-4	Not Assessed under the IRIS program.
75	Bis(2-chloro-1-methylethyl) ether	108-60-1	Not Assessed under the IRIS program.
76	Bis(2-chloroethoxy)methane	111-91-1	Not Assessed under the IRIS program.
77	Bis(chloroethyl)ether (BCEE)	111-44-4	Hepatomas	Linearized multistage procedure, extra risk	per µg /m3	3.3x10-4	Oral, Gavage followed by diet
78	Bis(chloromethyl)ether (BCME)	542-88-1	Respiratory tract tumors	Linearized multistage procedure, extra risk	per µg /m3	6.2x10-2	Inhalation
79	Bisphenol A.	80-05-7	Not Assessed under the IRIS program.
80	Boron and Compounds	7440-42-8	Not Assessed under the IRIS program.
81	Bromate	15541-45-4	Information reviewed but value not estimated. Refer to IRIS Summary.
82	Brominated dibenzofurans	NA	Not Assessed under the IRIS program.
83	Bromobenzene	108-86-1	Not Assessed under the IRIS program.
84	Bromochloromethane	74-97-5	Not Assessed under the IRIS program.
85	Bromodichloromethane	75-27-4	Not Assessed under the IRIS program.
86	p-Bromodiphenyl ether	101-55-3	Not Assessed under the IRIS program.
87	Bromoform	75-25-2	Neoplastic lesions in the large intestine	Linearized multistage procedure, extra risk	per µg /m3	1.1x10-6	Oral, Gavage in corn oil
88	Bromomethane	74-83-9	Not Assessed under the IRIS program.
89	Bromotrichloromethane	75-62-7	Not Assessed under the IRIS program.
90	Bromoxynil	1689-84-5	Not Assessed under the IRIS program.
91	Bromoxynil octanoate	1689-99-2	Not Assessed under the IRIS program.
92	1,3-Butadiene	106-99-0	Leukemia	Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied.	per µg /m3	3x10-5	Inhalation
93	n-Butanol	71-36-3	Not Assessed under the IRIS program.
94	Butyl benzyl phthalate	85-68-7	Not Assessed under the IRIS program.
95	Butylate	2008-41-5	Not Assessed under the IRIS program.
96	t-Butylchloride	507-20-0	Not Assessed under the IRIS program.
97	Butylphthalyl butylglycolate (BPBG)	85-70-1	Not Assessed under the IRIS program.
98	Cacodylic acid	75-60-5	Not Assessed under the IRIS program.
99	Cadmium	7440-43-9	Lung, trachea, bronchus cancer deaths	Two stage; only first affected by exposure; extra risk	per µg /m3	1.8x10-3	Inhalation, Exposure in the workplace
100	Calcium cyanide	592-01-8	Not Assessed under the IRIS program.
101	Caprolactam	105-60-2	Not Assessed under the IRIS program.
102	Captafol	2425-06-1	Not Assessed under the IRIS program.
103	Captan	133-06-2	Not Assessed under the IRIS program.
104	Carbary	l63-25-2	Not Assessed under the IRIS program.
105	Carbofuran1	563-66-2	Not Assessed under the IRIS program.
106	Carbon disulfide	75-15-0	Not Assessed under the IRIS program.
107	Carbon tetrachloride	56-23-5	Pheochromocytoma	Log-probit model with linear extrapolation from the POD (LEC10).	per µg /m3	6x10-6	Inhalation
108	Carbonyl sulfide	463-58-1	Not Assessed under the IRIS program.
109	Carbosulfan	55285-14-8	Not Assessed under the IRIS program.
110	Carboxin	5234-68-4	Not Assessed under the IRIS program.
111	Cerium Oxide and Cerium Compounds	1306-38-3	Not Assessed under the IRIS program.
112	Chloral hydrate	302-17-0	Not Assessed under the IRIS program.
113	Chloramben	133-90-4	Not Assessed under the IRIS program.
114	Chlordane (Technical)	12789-03-6	Hepatocellular carcinoma	Linearized multistage procedure, extra risk	per µg /m3	1x10-4<7sup>	Oral, Diet
115	Chlordecone (Kepone)	143-50-0	Information reviewed but value not estimated. Refer to IRIS Summary.
116	Chlorimuron-ethyl	90982-32-4	Not Assessed under the IRIS program.
117	Chlorine	7782-50-5	Not Assessed under the IRIS program.
118	Chlorine cyanide	506-77-4	Not Assessed under the IRIS program.
119	Chlorine dioxide	10049-04-4	Not Assessed under the IRIS program.
120	Chlorite (sodium salt)	7758-19-2	Not Assessed under the IRIS program.
121	1-Chloro-1,1-difluoroethane	75-68-3	Not Assessed under the IRIS program.
122	2-Chloroacetophenone	532-27-4	Not Assessed under the IRIS program.
123	p-Chloroaniline	106-47-8	Not Assessed under the IRIS program.
124	Chlorobenzene	108-90-7	Not Assessed under the IRIS program.
125	Chlorobenzilate	510-15-6	Not Assessed under the IRIS program.
126	1-Chlorobutane	109-69-3	Not Assessed under the IRIS program.
127	2-Chlorobutane	78-86-4	Not Assessed under the IRIS program.
128	Chlorocyclopentadiene	41851-50-7	Not Assessed under the IRIS program.
129	Chlorodifluoromethane	75-45-6	Not Assessed under the IRIS program.
130	Chloroform	67-66-3	Hepatocellular carcinoma	Linearized multistage procedure, extra risk	per µg /m3	2.3x10-5	Oral, Gavage
131	Chloromethyl methyl ether (CMME)	107-30-2	Not Assessed under the IRIS program.
132	beta-Chloronaphthalene	91-58-7	Not Assessed under the IRIS program.
133	2-Chlorophenol	95-57-8	Not Assessed under the IRIS program.
134	p-Chlorophenyl methyl sulfide	123-09-1	Not Assessed under the IRIS program.
135	p-Chlorophenyl methyl sulfone	98-57-7	Not Assessed under the IRIS program.
136	p-Chlorophenyl methyl sulfoxide	934-73-6	Not Assessed under the IRIS program.
137	Chloroprene	126-99-8	alveolar/ bronchiolar adenoma or carcinoma; hemangioma/ hemangiosarcoma (all organs); mammary gland adenocarcinoma, carcinoma, or adenoacanthoma; forestomach squamous cell papilloma or carcinoma; hepatocellular adenoma or carcinoma; Harderian gland adenoma or carcinoma; skin sarcoma; and Zymbal's gland carcinoma	Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.	per µg /m3	3x10-4	Inhalation
138	Chlorothalonil	1897-45-6	Not Assessed under the IRIS program.
139	o-Chlorotoluene	95-49-8	Not Assessed under the IRIS program.
140	Chlorpropham	101-21-3	Not Assessed under the IRIS program.
141	Chlorpyrifos	2921-88-2	Not Assessed under the IRIS program.
142	Chlorsulfuron	64902-72-3	Not Assessed under the IRIS program.
143	Chromium(III), insoluble salts	16065-83-1	Not Assessed under the IRIS program.
144	Chromium(VI)	18540-29-9	Lung cancer	Multistage, extra risk	per µg /m3	1.2x10-2	Inhalation, Occupational exposure
145	Chrysene	218-01-9	Not Assessed under the IRIS program.
146	Coke oven emissions	8007-45-2	Respiratory cancer	Linearized multistage procedure	per µg /m3	6.2x10-4	Inhalation, Occupational
147	Copper	7440-50-8	Not Assessed under the IRIS program.
148	Copper cyanide	544-92-3	Not Assessed under the IRIS program.
149	Creosote	8001-58-9	Not Assessed under the IRIS program.
150	Crotonaldehyde	123-73-9	Not Assessed under the IRIS program.
151	Cumene	98-82-8	Not Assessed under the IRIS program.
152	Cyanazine	21725-46-2	Not Assessed under the IRIS program.
153	Cyanide, free	57-12-5	Not Assessed under the IRIS program.
154	Cyanogen	460-19-5	Not Assessed under the IRIS program.
155	Cyanogen bromide	506-68-3	Not Assessed under the IRIS program.
156	Cyclohexane	110-82-7	Not Assessed under the IRIS program.
157	Cyclohexanone	108-94-1	Not Assessed under the IRIS program.
158	Cyclohexylamine	108-91-8	Not Assessed under the IRIS program.
159	Cyhalothrin/Karate	68085-85-8	Not Assessed under the IRIS program.
160	Cypermethrin	52315-07-8	Not Assessed under the IRIS program.
161	Cyromazine	66215-27-8	Not Assessed under the IRIS program.
162	Dacthal	1861-32-1	Not Assessed under the IRIS program.
163	Dalapon, sodium salt	75-99-0	Not Assessed under the IRIS program.
164	Danitol	39515-41-8	Not Assessed under the IRIS program.
165	2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209)	1163-19-5	Not Assessed under the IRIS program.
166	Demeton	8065-48-3	Not Assessed under the IRIS program.
167	Di (2-ethylhexyl)phthalate (DEHP)	117-81-7	Not Assessed under the IRIS program.
168	Di(2-ethylhexyl)adipate	103-23-1	Not Assessed under the IRIS program.
169	2,4-Diaminotoluene	95-80-7	Not Assessed under the IRIS program.
170	Diazomethane	334-88-3	Not Assessed under the IRIS program.
171	Dibenz[a,h]anthracene	53-70-3	Not Assessed under the IRIS program.
172	Dibenzofuran	132-64-9	Not Assessed under the IRIS program.
173	1,2-Dibromo-3-chloropropane (DBCP)	96-12-8	Not Assessed under the IRIS program.
174	1,4-Dibromobenzene	106-37-6	Not Assessed under the IRIS program.
175	Dibromochloromethane	124-48-1	Not Assessed under the IRIS program.
176	Dibromodichloromethane	594-18-3	Not Assessed under the IRIS program.
177	p,p'-Dibromodiphenyl ether	2050-47-7	Not Assessed under the IRIS program.
178	1,2-Dibromoethane	106-93-4	Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas	Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.	per µg /m3	6x10-4	Inhalation
179	1,2-Dibromoethane	106-93-4	Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas	Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range.	per µg /m3	3x10-4	Inhalation
180	Dibutyl phthalate	84-74-2	Not Assessed under the IRIS program.
181	Dicamba	1918-00-9	Not Assessed under the IRIS program.
182	Dichloroacetic acid	79-43-6	Information reviewed but value not estimated. Refer to IRIS Summary.
183	1,3-Dichlorobenzene	541-73-1	Not Assessed under the IRIS program.
184	1,4-Dichlorobenzene	106-46-7	Not Assessed under the IRIS program.
185	1,2-Dichlorobenzene	95-50-1	Not Assessed under the IRIS program.
186	3,3'-Dichlorobenzidine	91-94-1	Not Assessed under the IRIS program.
187	Dichlorodifluoromethane	75-71-8	Not Assessed under the IRIS program.
188	p,p'-Dichlorodiphenyl dichloroethane (DDD)	72-54-8	Not Assessed under the IRIS program.
189	p,p'-Dichlorodiphenyldichloroethylene (DDE)	72-55-9	Not Assessed under the IRIS program.
190	p,p'-Dichlorodiphenyltrichloroethane (DDT)	50-29-3	Liver tumors, benign and malignant	Linear multistage procedure, extra risk	per µg /m3	9.7x10-5	Oral,Diet
191	1,2-Dichloroethane	107-06-2	Hemangiosarcomas	Linearized multistage procedure, extra risk	per µg /m3	2.6x10-5	Oral,Gavage
192	1,1-Dichloroethane	75-34-3	Not Assessed under the IRIS program.
193	trans-1,2-Dichloroethylene	156-60-5	Not Assessed under the IRIS program.
194	cis-1,2-Dichloroethylene	156-59-2	Not Assessed under the IRIS program.
195	1,1-Dichloroethylene (1,1-DCE)	75-35-4	Information reviewed but value not estimated. Refer to IRIS Summary.
196	Dichloromethane	75-09-2	Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas	Multistage model with linear extrapolation from the point of departure (BMDL10)	per µg /m3	1x10-8	Inhalation
197	2,4-Dichlorophenol	120-83-2	Not Assessed under the IRIS program.
198	4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB)	94-82-6	Not Assessed under the IRIS program.
199	2,4-Dichlorophenoxyacetic acid (2,4-D)	94-75-7	Not Assessed under the IRIS program.
200	1,2-Dichloropropane	78-87-5	Not Assessed under the IRIS program.
201	2,3-Dichloropropanol	616-23-9	Not Assessed under the IRIS program.
202	1,3-Dichloropropene	542-75-6	Bronchioalveolar adenoma	Linearized multistage model, extra risk	per µg /m3	4x10-6	Inhalation
203	Dichlorvos	62-73-7	Not Assessed under the IRIS program.
204	Dicofol	115-32-2	Not Assessed under the IRIS program.
205	Dieldrin	60-57-1	Liver carcinoma	Linearized multistage procedure, extra risk	per µg /m3	4.6x10-3	Oral, Diet
206	Diesel engine exhaust	NA	Information reviewed but value not estimated. Refer to IRIS Summary.
207	Diethyl phthalate	84-66-2	Not Assessed under the IRIS program.
208	Diethyl sulfate	64-67-5	Not Assessed under the IRIS program.
209	Diethyl-p-nitrophenylphosphate	311-45-5	Not Assessed under the IRIS program.
210	Diethylene glycol dinitrate (DEGDN)	693-21-0	Not Assessed under the IRIS program.
211	Difenzoquat	43222-48-6	Not Assessed under the IRIS program.
212	Diflubenzuron	35367-38-5	Not Assessed under the IRIS program.
213	1,1-Difluoroethane	75-37-6	Not Assessed under the IRIS program.
214	Diisopropyl methylphosphonate (DIMP)	1445-75-6	Not Assessed under the IRIS program.
215	Dimethipin	55290-64-7	Not Assessed under the IRIS program.
216	Dimethoate	60-51-5	Not Assessed under the IRIS program.
217	Dimethyl phthalate	131-11-3	Not Assessed under the IRIS program.
218	Dimethyl sulfate	77-78-1	Not Assessed under the IRIS program.
219	Dimethyl terephthalate (DMT)	120-61-6	Not Assessed under the IRIS program.
220	Dimethylamine	124-40-3	Not Assessed under the IRIS program.
221	N-N-Dimethylaniline	121-69-7	Not Assessed under the IRIS program.
222	3,3-Dimethylbenzidine	119-93-7	Not Assessed under the IRIS program.
223	N,N-Dimethylformamide	68-12-2	Not Assessed under the IRIS program.
224	3,4-Dimethylphenol	95-65-8	Not Assessed under the IRIS program.
225	2,6-Dimethylphenol	576-26-1	Not Assessed under the IRIS program.
226	2,4-Dimethylphenol	105-67-9	Not Assessed under the IRIS program.
227	4,6-Dinitro-o-cyclohexyl phenol	131-89-5	Not Assessed under the IRIS program.
228	m-Dinitrobenzene	99-65-0	Not Assessed under the IRIS program.
229	o-Dinitrobenzene	528-29-0	Not Assessed under the IRIS program.
230	2,4-Dinitrophenol	51-28-5	Not Assessed under the IRIS program.
231	2,4-Dinitrotoluene	121-14-2	Not Assessed under the IRIS program.
232	2,4-/2,6-Dinitrotoluene mixture	NA	Not Assessed under the IRIS program.
233	Dinoseb	88-85-7	Not Assessed under the IRIS program.
234	1,4-Dioxane	123-91-1	Information reviewed but value not estimated. Refer to IRIS Summary.
235	Diphenamid	957-51-7	Not Assessed under the IRIS program.
236	Diphenylamine	122-39-4	Not Assessed under the IRIS program.
237	1,2-Diphenylhydrazine	122-66-7	Hepatocellular carcinomas and neoplastic liver nodules	Linearized multistage procedure, extra risk	per µg /m3	2.2x10-4	Oral, Diet
238	Diquat	85-00-7	Not Assessed under the IRIS program.
239	Disulfoton	298-04-4	Not Assessed under the IRIS program.
240	1,4-Dithiane	505-29-3	Not Assessed under the IRIS program.
241	Diuron	330-54-1	Not Assessed under the IRIS program.
242	Dodine	2439-10-3	Not Assessed under the IRIS program.
243	Endosulfan	115-29-7	Not Assessed under the IRIS program.
244	Endothall	145-73-3	Not Assessed under the IRIS program.
245	Endrin	72-20-8	Not Assessed under the IRIS program.
246	Epichlorohydrin	106-89-8	Nasal cavity tumors	Linearized multistage procedure, extra risk	per µg /m3	1.2x10-6	Inhalation
247	1,2-Epoxybutane (EBU)	106-88-7	Not Assessed under the IRIS program.
248	Ethephon	16672-87-0	Not Assessed under the IRIS program.
249	Ethion	563-12-2	Not Assessed under the IRIS program.
250	2-Ethoxyethanol	110-80-5	Not Assessed under the IRIS program.
251	Ethyl acetate	141-78-6	Not Assessed under the IRIS program.
252	Ethyl carbamate	51-79-6	Not Assessed under the IRIS program.
253	Ethyl chloride	75-00-3	Not Assessed under the IRIS program.
254	S-Ethyl dipropylthiocarbamate (EPTC)	759-94-4	Not Assessed under the IRIS program.
255	Ethyl ether	60-29-7	Not Assessed under the IRIS program.
256	Ethyl p-nitrophenyl phenylphosphorothioate (EPN)	2104-64-5	Not Assessed under the IRIS program.
257	Ethylbenzene	100-41-4	Not Assessed under the IRIS program.
258	Ethylene diamine	107-15-3	Not Assessed under the IRIS program.
259	Ethylene glycol	107-21-1	Not Assessed under the IRIS program.
260	Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol)	111-76-2	Information reviewed but value not estimated. Refer to IRIS Summary.
261	Ethylene thiourea (ETU)	96-45-7	Not Assessed under the IRIS program.
262	Ethyleneimine	151-56-4	Not Assessed under the IRIS program.
263	Ethylphthalyl ethylglycolate (EPEG)	84-72-0	Not Assessed under the IRIS program.
264	Express	101200-48-0	Not Assessed under the IRIS program.
265	Fenamiphos	22224-92-6	Not Assessed under the IRIS program.
266	Fluometuron	2164-17-2	Not Assessed under the IRIS program.
267	Fluoranthene	206-44-0	Not Assessed under the IRIS program.
268	Fluorene	86-73-7	Not Assessed under the IRIS program.
269	Fluorine (soluble fluoride)	7782-41-4	Not Assessed under the IRIS program.
270	Fluridone	59756-60-4	Not Assessed under the IRIS program.
271	Flurprimidol	56425-91-3	Not Assessed under the IRIS program.
272	Flutolanil	66332-96-5	Not Assessed under the IRIS program.
273	Fluvalinate	69409-94-5	Not Assessed under the IRIS program.
274	Folpet	133-07-3	Not Assessed under the IRIS program.
275	Fomesafen	72178-02-0	Not Assessed under the IRIS program.
276	Fonofos	944-22-9	Not Assessed under the IRIS program.
277	Formaldehyde	50-00-0	Squamous cell carcinoma	Linearized multistage procedure, additional risk	per µg /m3	1.3x10-5	Inhalation
278	Formic acid	64-18-6	Not Assessed under the IRIS program.
279	Fosetyl-al	39148-24-8	Not Assessed under the IRIS program.
280	Furan	110-00-9	Not Assessed under the IRIS program.
281	Furfural	98-01-1	Not Assessed under the IRIS program.
282	Furmecyclox	60568-05-0	Not Assessed under the IRIS program.
283	Glufosinate-ammonium	77182-82-2	Not Assessed under the IRIS program.
284	Glycidaldehyde	765-34-4	Not Assessed under the IRIS program.
285	Glyphosate	1071-83-6	Not Assessed under the IRIS program.
286	Haloxyfop-methyl	69806-40-2	Not Assessed under the IRIS program.
287	Harmony	79277-27-3	Not Assessed under the IRIS program.
288	Heptachlor	76-44-8	Hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg/m3	1.3x10-3	Oral, Diet
289	Heptachlor epoxide	1024-57-3	Hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg/m3	2.6x10-3	Oral, Diet
290	n-Heptane	142-82-5	Not Assessed under the IRIS program.
291	Hexabromobenzene	87-82-1	Not Assessed under the IRIS program.
292	Hexabromodiphenyl ether	36483-60-0	Not Assessed under the IRIS program.
293	2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153)	68631-49-2	Not Assessed under the IRIS program.
294	Hexachlorobenzene	118-74-1	Hepatocellular carcinoma	Linearized multistage, extra risk	per µg /m3	4.6x10-4	Oral, Diet
295	Hexachlorobutadiene	87-68-3	Renal tubular adenomas and adenocarcinomas	Linearized multistage procedure, extra risk	per µg /m3	2.2x10-5	Oral, Diet
296	alpha-Hexachlorocyclohexane (alpha-HCH)	319-84-6	Hepatic nodules and hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg /m3	1.8x10-3	Oral, Diet
297	beta-Hexachlorocyclohexane (beta-HCH)	319-85-7	Hepatic nodules and hepatocellular carcinomas	Linearized multistage procedure, extra risk	per µg /m3	5.3x10-4	Oral, Diet
298	delta-Hexachlorocyclohexane (delta-HCH)	319-86-8	Not Assessed under the IRIS program.
299	epsilon-Hexachlorocyclohexane (epsilon-HC)	6108-10-7	Not Assessed under the IRIS program.
300	gamma-Hexachlorocyclohexane (gamma-HCH)	58-89-9	Not Assessed under the IRIS program.
301	technical Hexachlorocyclohexane (t-HCH)	608-73-1	Liver nodules and hepatocellular carcinomas	Linearized multistage procedure	per µg /m3	5.1x10-4	Oral, Diet
302	Hexachlorocyclopentadiene (HCCPD)	77-47-4	Not Assessed under the IRIS program.
303	Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD	57653-85-7	Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas)	Linearized multistage procedure, extra risk	per µg /m3	1.3	Oral, Gavage
304	Hexachloroethane	67-72-1	Information reviewed but value not estimated. Refer to IRIS Summary.
305	Hexachlorophene	70-30-4	Not Assessed under the IRIS program.
306	Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)	121-82-4	Not Assessed under the IRIS program.
307	1,6-Hexamethylene diisocyanate	822-06-0	Not Assessed under the IRIS program.
308	n-Hexane	110-54-3	Not Assessed under the IRIS program.
309	2-Hexanone	591-78-6	Not Assessed under the IRIS program.
310	Hexazinone	51235-04-2	Not Assessed under the IRIS program.
311	Hydrazine/Hydrazine sulfate	302-01-2	Nasal cavity adenoma or adenocarcinoma	Linearized multistage procedure, extra risk	per µg /m3	4.9x10-3	Inhalation
312	Hydrogen Cyanide and Cyanide Salts	Various	Not Assessed under the IRIS program.
313	Hydrogen chloride	7647-01-0	Not Assessed under the IRIS program.
314	Hydrogen sulfide	7783-06-4	Not Assessed under the IRIS program.
315	Hydroquinone	123-31-9	Not Assessed under the IRIS program.
316	Imazalil	35554-44-0	Not Assessed under the IRIS program.
317	Imazaquin	81335-37-7	Not Assessed under the IRIS program.
318	Indeno[1,2,3-cd]pyrene	193-39-5	Not Assessed under the IRIS program.
319	Iprodione	36734-19-7	Not Assessed under the IRIS program.
320	Isobutyl alcohol	78-83-1	Not Assessed under the IRIS program.
321	Isophorone	78-59-1	Not Assessed under the IRIS program.
322	Isopropalin	33820-53-0	Not Assessed under the IRIS program.
323	Isopropyl methyl phosphonic acid (IMPA)	1832-54-8	Not Assessed under the IRIS program.
324	Isoxaben	82558-50-7	Not Assessed under the IRIS program.
325	Lactofen	77501-63-4	Not Assessed under the IRIS program.
326	Lead and compounds (inorganic)	7439-92-1	Not Assessed under the IRIS program.
327	d-Limonene	5989-27-5	Not Assessed under the IRIS program.
328	Linuron	330-55-2	Not Assessed under the IRIS program.
329	Londax	83055-99-6	Not Assessed under the IRIS program.
330	Malathion	121-75-5	Not Assessed under the IRIS program.
331	Maleic anhydride	108-31-6	Not Assessed under the IRIS program.
332	Maleic hydrazide	123-33-1	Not Assessed under the IRIS program.
333	Maneb	12427-38-2	Not Assessed under the IRIS program.
334	Manganese	7439-96-5	Not Assessed under the IRIS program.
335	Mepiquat chloride	24307-26-4	Not Assessed under the IRIS program.
336	Mercuric chloride (HgCl2)	7487-94-7	Not Assessed under the IRIS program.
337	Mercury, elemental	7439-97-6	Not Assessed under the IRIS program.
338	Merphos	150-50-5	Not Assessed under the IRIS program.
339	Merphos oxide	78-48-8	Not Assessed under the IRIS program.
340	Metalaxyl	57837-19-1	Not Assessed under the IRIS program.
341	Methacrylonitrile	126-98-7	Not Assessed under the IRIS program.
342	Methamidophos	10265-92-6	Not Assessed under the IRIS program.
343	Methanol	67-56-1	Not Assessed under the IRIS program.
344	Methidathion	950-37-8	Not Assessed under the IRIS program.
345	Methomyl	16752-77-5	Not Assessed under the IRIS program.
346	Methoxychlor	72-43-5	Not Assessed under the IRIS program.
347	2-Methoxyethanol	109-86-4	Not Assessed under the IRIS program.
348	Methyl acrylate	96-33-3	Not Assessed under the IRIS program.
349	Methyl chloride	74-87-3	Not Assessed under the IRIS program.
350	Methyl chlorocarbonate	79-22-1	Not Assessed under the IRIS program.
351	Methyl ethyl ketone (MEK)	78-93-3	Not Assessed under the IRIS program.
352	Methyl iodide	74-88-4	Not Assessed under the IRIS program.
353	Methyl isobutyl ketone (MIBK)	108-10-1	Not Assessed under the IRIS program.
354	Methyl isocyanate	624-83-9	Not Assessed under the IRIS program.
355	Methyl methacrylate	80-62-6	Not Assessed under the IRIS program.
356	Methyl parathion	298-00-0	Not Assessed under the IRIS program.
357	Methyl tert-butyl ether (MTBE)	1634-04-4	Not Assessed under the IRIS program.
358	4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB)	94-81-5	Not Assessed under the IRIS program.
359	2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP)	93-65-2	Not Assessed under the IRIS program.
360	2-Methyl-4-chlorophenoxyacetic acid (MCPA)	94-74-6	Not Assessed under the IRIS program.
361	Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI)	101-68-8	Not Assessed under the IRIS program.
362	4,4'-Methylene bis(N,N'-dimethyl)aniline	101-61-1	Not Assessed under the IRIS program.
363	Methylmercury (MeHg)	22967-92-6	Not Assessed under the IRIS program.
364	2-Methylnaphthalene	91-57-6	Not Assessed under the IRIS program.
365	2-Methylphenol	95-48-7	Not Assessed under the IRIS program.
366	4-Methylphenol	106-44-5	Not Assessed under the IRIS program.
367	3-Methylphenol	108-39-4	Not Assessed under the IRIS program.
368	Metolachlor	51218-45-2	Not Assessed under the IRIS program.
369	Metribuzin	21087-64-9	Not Assessed under the IRIS program.
370	Mirex	2385-85-5	Not Assessed under the IRIS program.
371	Molinate	2212-67-1	Not Assessed under the IRIS program.
372	Molybdenum	7439-98-7	Not Assessed under the IRIS program.
373	Monochloramine	10599-90-3	Not Assessed under the IRIS program.
374	Naled	300-76-5	Not Assessed under the IRIS program.
375	Naphthalene	91-20-3	Information reviewed but value not estimated. Refer to IRIS Summary.
376	Napropamide	15299-99-7	Not Assessed under the IRIS program.
377	Nickel carbonyl	13463-39-3	Not Assessed under the IRIS program.
378	Nickel refinery dust	NA	Lung cancer	Additive and multiplicative	per µg /m3	2.4x10-4	Inhalation
379	Nickel subsulfide	12035-72-2	Lung cancer	Additive and multiplicative	per µg /m3	4.8x10-4	Inhalation
380	Nickel, soluble salts	NA	Not Assessed under the IRIS program.
381	Nitrapyrin	1929-82-4	Not Assessed under the IRIS program.
382	Nitrate	14797-55-8	Not Assessed under the IRIS program.
383	Nitric oxide	10102-43-9	Not Assessed under the IRIS program.
384	Nitrite	14797-65-0	Not Assessed under the IRIS program.
385	Nitrobenzene	98-95-3	Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas	Multistage model with linear extrapolation from the POD (LEC10).	per µg /m3	4x10-5	Inhalation
386	Nitrogen dioxide	10102-44-0	Not Assessed under the IRIS program.
387	Nitroguanidine	556-88-7	Not Assessed under the IRIS program.
388	p-Nitrophenol	100-02-7	Not Assessed under the IRIS program.
389	2-Nitropropane	79-46-9	Not Assessed under the IRIS program.
390	N-Nitroso-N-methylethylamine	10595-95-6	Not Assessed under the IRIS program.
391	N-Nitroso-di-n-butylamine	924-16-3	Bladder and esophagus tumors	Linearized multistage procedure, extra risk	per µg /m3	1.6x10-3	Oral, Drinking water
392	N-Nitrosodi-N-propylamine	621-64-7	Not Assessed under the IRIS program.
393	N-Nitrosodiethanolamine	1116-54-7	Not Assessed under the IRIS program.
394	N-Nitrosodiethylamine	55-18-5	Liver tumors	Weibull, extra risk	per µg /m3	4.3x10-2	Oral, Drinking water
395	N-Nitrosodimethylamine	62-75-9	Liver tumors	Weibull, extra risk	per µg /m3	1.4x10-2	Oral, Drinking water
396	N-Nitrosodiphenylamine	86-30-6	Not Assessed under the IRIS program.
397	N-Nitrosopyrrolidine	930-55-2	Hepatocellular carcinoma and adenoma	Linearized multistage procedure, extra risk	per µg /m3	6.1x10-4	Oral, Diet
398	Nonabromodiphenyl ether	63936-56-1	Not Assessed under the IRIS program.
399	Norflurazon	27314-13-2	Not Assessed under the IRIS program.
400	NuStar	85509-19-9	Not Assessed under the IRIS program.
401	Octabromodiphenyl ether	32536-52-0	Not Assessed under the IRIS program.
402	Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX)	2691-41-0	Not Assessed under the IRIS program.
403	Oryzalin	19044-88-3	Not Assessed under the IRIS program.
404	Oxadiazon	19666-30-9	Not Assessed under the IRIS program.
405	Oxamyl	23135-22-0	Not Assessed under the IRIS program.
406	Oxyfluorfen	42874-03-3	Not Assessed under the IRIS program.
407	Paclobutrazol	76738-62-0	Not Assessed under the IRIS program.
408	Paraquat	1910-42-5	Not Assessed under the IRIS program.
409	Parathion	56-38-2	Not Assessed under the IRIS program.
410	Pendimethalin	40487-42-1	Not Assessed under the IRIS program.
411	Pentabromodiphenyl ether	32534-81-9	Not Assessed under the IRIS program.
412	2,2',4,4',5-Pentabromodiphenyl ether (BDE-99)	60348-60-9	Not Assessed under the IRIS program.
413	Pentachlorobenzene	608-93-5	Not Assessed under the IRIS program.
414	Pentachlorocyclopentadiene	25329-35-5	Not Assessed under the IRIS program.
415	Pentachloronitrobenzene (PCNB)	82-68-8	Not Assessed under the IRIS program.
416	Pentachlorophenol	87-86-5	Not Assessed under the IRIS program.
417	Pentafluoroethane	354-33-6	Not Assessed under the IRIS program.
418	Perchlorate (ClO4) and Perchlorate Salts	7790-98-9	Not Assessed under the IRIS program.
419	Permethrin	52645-53-1	Not Assessed under the IRIS program.
420	Phenanthrene	85-01-8	Not Assessed under the IRIS program.
421	Phenmedipham	13684-63-4	Not Assessed under the IRIS program.
422	Phenol	108-95-2	Not Assessed under the IRIS program.
423	m-Phenylenediamine	108-45-2	Not Assessed under the IRIS program.
424	Phenylmercuric acetate	62-38-4	Not Assessed under the IRIS program.
425	Phosalone	2310-17-0	Not Assessed under the IRIS program.
426	Phosgene	75-44-5	Not Assessed under the IRIS program.
427	Phosmet	732-11-6	Not Assessed under the IRIS program.
428	Phosphine	7803-51-2	Not Assessed under the IRIS program.
429	Phosphoric acid	7664-38-2	Not Assessed under the IRIS program.
430	Phthalic anhydride	85-44-9	Not Assessed under the IRIS program.
431	Picloram	1918-02-1	Not Assessed under the IRIS program.
432	Pirimiphos-methyl	29232-93-7	Not Assessed under the IRIS program.
433	Polychlorinated biphenyls (PCBs)	1336-36-3	Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas	Linear extrapolation below LED10s	per µg /m3	1x10-4	Oral, Diet
434	Potassium cyanide	151-50-8	Not Assessed under the IRIS program.
435	Potassium silver cyanide	506-61-6	Not Assessed under the IRIS program.
436	Prochloraz	67747-09-5	Not Assessed under the IRIS program.
437	Prometon	1610-18-0	Not Assessed under the IRIS program.
438	Prometryn	7287-19-6	Not Assessed under the IRIS program.
439	Pronamide	23950-58-5	Not Assessed under the IRIS program.
440	Propachlor	1918-16-7	Not Assessed under the IRIS program.
441	Propanil	709-98-8	Not Assessed under the IRIS program.
442	Propargite	2312-35-8	Not Assessed under the IRIS program.
443	Propargyl alcohol	107-19-7	Not Assessed under the IRIS program.
444	Propazine	139-40-2	Not Assessed under the IRIS program.
445	Propham	122-42-9	Not Assessed under the IRIS program.
446	Propiconazole	60207-90-1	Not Assessed under the IRIS program.
447	beta-Propiolactone	57-57-8	Not Assessed under the IRIS program.
448	Propionaldehyde	123-38-6	Not Assessed under the IRIS program.
449	Propylene glycol	57-55-6	Not Assessed under the IRIS program.
450	Propylene glycol monoethyl ether	52125-53-8	Not Assessed under the IRIS program.
451	Propylene glycol monomethyl ether (PGME)	107-98-2	Not Assessed under the IRIS program.
452	Propylene oxide	75-56-9	Nasal cavity hemangioma or hemangiosarcoma	Linearized multistage procedure, extra risk	per µg /m3	3.7x10-6	Inhalation
453	Propyleneimine	75-55-8	Not Assessed under the IRIS program.
454	Pursuit	81335-77-5	Not Assessed under the IRIS program.
455	Pydrin	51630-58-1	Not Assessed under the IRIS program.
456	Pyrene	129-00-0	Not Assessed under the IRIS program.
457	Pyridine	110-86-1	Not Assessed under the IRIS program.
458	Quinalphos	13593-03-8	Not Assessed under the IRIS program.
459	Quinoline	91-22-5	Information reviewed but value not estimated. Refer to IRIS Summary.
460	Quinone	106-51-4	Not Assessed under the IRIS program.
461	Radium 226,228	7440-14-4	Not Assessed under the IRIS program.
462	Radon 222	14859-67-7	Not Assessed under the IRIS program.
463	Refractory ceramic fibers	NA	Information reviewed but value not estimated. Refer to IRIS Summary.
464	Resmethrin	10453-86-8	Not Assessed under the IRIS program.
465	Rotenone	83-79-4	Not Assessed under the IRIS program.
466	Savey	78587-05-0	Not Assessed under the IRIS program.
467	Selenious acid	7783-00-8	Not Assessed under the IRIS program.
468	Selenium and Compounds	7782-49-2	Not Assessed under the IRIS program.
469	Selenium sulfide	7446-34-6	Not Assessed under the IRIS program.
470	Selenourea	630-10-4	Not Assessed under the IRIS program.
471	Sethoxydim	74051-80-2	Not Assessed under the IRIS program.
472	Silver	7440-22-4	Not Assessed under the IRIS program.
473	Silver cyanide	506-64-9	Not Assessed under the IRIS program.
474	Simazine	122-34-9	Not Assessed under the IRIS program.
475	Sodium azide	26628-22-8	Not Assessed under the IRIS program.
476	Sodium cyanide	143-33-9	Not Assessed under the IRIS program.
477	Sodium diethyldithiocarbamate	148-18-5	Not Assessed under the IRIS program.
478	Sodium fluoroacetate	62-74-8	Not Assessed under the IRIS program.
479	Strontium	7440-24-6	Not Assessed under the IRIS program.
480	Strychnine	57-24-9	Not Assessed under the IRIS program.
481	Styrene	100-42-5	Not Assessed under the IRIS program.
482	Systhane	88671-89-0	Not Assessed under the IRIS program.
483	Tebuthiuron	34014-18-1	Not Assessed under the IRIS program.
484	Terbacil	5902-51-2	Not Assessed under the IRIS program.
485	Terbutryn	886-50-0	Not Assessed under the IRIS program.
486	Tetrabromodiphenyl ether	40088-47-9	Not Assessed under the IRIS program.
487	2,2',4,4'-Tetrabromodiphenyl ether (BDE-47)	5436-43-1	Not Assessed under the IRIS program.
488	1,2,4,5-Tetrachlorobenzene	95-94-3	Not Assessed under the IRIS program.
489	Tetrachlorocyclopentadiene	695-77-2	Not Assessed under the IRIS program.
490	1,1,1,2-Tetrachloroethane	630-20-6	Hepatocellular adenoma or carcinoma	Linearized multistage procedure, extra risk	per µg /m3	7.4x10-6	Oral, Gavage
491	1,1,2,2-Tetrachloroethane	79-34-5	Information reviewed but value not estimated. Refer to IRIS Summary.
492	Tetrachloroethylene	127-18-4	Not Assessed under the IRIS program.
493	2,3,4,6-Tetrachlorophenol	58-90-2	Not Assessed under the IRIS program.
494	Tetrachlorovinphos	961-11-5	Not Assessed under the IRIS program.
495	Tetraethyl lead	78-00-2	Not Assessed under the IRIS program.
496	Tetraethyldithiopyrophosphate	3689-24-5	Not Assessed under the IRIS program.
497	1,1,1,2-Tetrafluoroethane	811-97-2	Not Assessed under the IRIS program.
498	Thallium (I), soluble salts	Various	Not Assessed under the IRIS program.
499	Thallium acetate	563-68-8	Not Assessed under the IRIS program.
500	Thallium carbonate	6533-73-9	Not Assessed under the IRIS program.
501	Thallium chloride	7791-12-0	Not Assessed under the IRIS program.
502	Thallium nitrate	10102-45-1	Not Assessed under the IRIS program.
503	Thallium oxide	1314-32-5	Not Assessed under the IRIS program.
504	Thallium selenite	12039-52-0	Not Assessed under the IRIS program.
505	Thallium(I) sulfate	7446-18-6	Not Assessed under the IRIS program.
506	Thiobencarb	28249-77-6	Not Assessed under the IRIS program.
507	Thiophanate-methyl	23564-05-8	Not Assessed under the IRIS program.
508	Thiram	137-26-8	Not Assessed under the IRIS program.
509	Toluene	108-88-3	Not Assessed under the IRIS program.
510	2,4-/2,6-Toluene diisocyanate mixture (TDI)	26471-62-5	Not Assessed under the IRIS program.
511	Toxaphene	8001-35-2	Hepatocellular carcinomas and neoplastic nodules	Linearized multistage procedure, extra risk	per µg /m3	3.2x10-4	Oral, Diet
512	Tralomethrin	66841-25-6	Not Assessed under the IRIS program.
513	Triallate	2303-17-5	Not Assessed under the IRIS program.
514	Triasulfuron	82097-50-5	Not Assessed under the IRIS program.
515	1,2,4-Tribromobenzene	615-54-3	Not Assessed under the IRIS program.
516	Tribromochloromethane	594-15-0	Not Assessed under the IRIS program.
517	Tribromodiphenyl ether	49690-94-0	Not Assessed under the IRIS program.
518	Tributyltin oxide (TBTO)	56-35-9	Not Assessed under the IRIS program.
519	1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113)	76-13-1	Not Assessed under the IRIS program.
520	Trichloroacetic acid	76-03-9	Information reviewed but value not estimated. Refer to IRIS Summary.
521	1,2,4-Trichlorobenzene	120-82-1	Not Assessed under the IRIS program.
522	Trichlorocyclopentadiene	77323-84-3	Not Assessed under the IRIS program.
523	1,1,2-Trichloroethane	79-00-5	Hepatocellular carcinoma	Linearized multistage procedure, extra risk	per µg /m3	1.6x10-5	Oral, Gavage
524	1,1,1-Trichloroethane	71-55-6	Information reviewed but value not estimated. Refer to IRIS Summary.
525	Trichloroethylene	79-01-6	Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors	Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk	per µg /m3	4.1x10-6	Inhalation
526	Trichlorofluoromethane	75-69-4	Not Assessed under the IRIS program.
527	2,4,5-Trichlorophenol	95-95-4	Not Assessed under the IRIS program.
528	2,4,6-Trichlorophenol	88-06-2	Leukemia	Linearized multistage procedure, extra risk	per µg /m3	3.1x10-6	Oral,Diet
529	2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP)	93-72-1	Not Assessed under the IRIS program.
530	2,4,5-Trichlorophenoxyacetic acid (2,4,5-T)	93-76-5	Not Assessed under the IRIS program.
531	1,1,2-Trichloropropane	598-77-6	Not Assessed under the IRIS program.
532	1,2,3-Trichloropropane	96-18-4	Not Assessed under the IRIS program.
533	Tricresol	1319-77-3	Not Assessed under the IRIS program.
534	Tridiphane	58138-08-2	Not Assessed under the IRIS program.
535	Triethylamine	121-44-8	Not Assessed under the IRIS program.
536	Triethylene glycol monobutyl ether	143-22-6	Not Assessed under the IRIS program.
537	Triethylene glycol monoethyl ether	112-50-5	Not Assessed under the IRIS program.
538	Trifluralin	1582-09-8	Not Assessed under the IRIS program.
539	2,2,4-Trimethylpentane	540-84-1	Not Assessed under the IRIS program.
540	1,3,5-Trinitrobenzene	99-35-4	Not Assessed under the IRIS program.
541	2,4,6-Trinitrotoluene (TNT)	118-96-7	Not Assessed under the IRIS program.
542	Uranium, natural	7440-61-1	Not Assessed under the IRIS program.
543	Uranium, soluble salts	NA	Not Assessed under the IRIS program.
544	Urea	57-13-6	Not Assessed under the IRIS program.
545	Vanadium pentoxide	1314-62-1	Not Assessed under the IRIS program.
546	Vernam	1929-77-7	Not Assessed under the IRIS program.
547	Vinclozolin	50471-44-8	Not Assessed under the IRIS program.
548	Vinyl acetate	108-05-4	Not Assessed under the IRIS program.
549	Vinyl bromide	593-60-2	Not Assessed under the IRIS program.
550	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LMS method	per µg /m3	4.4x10-6	Inhalation
551	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LED 10/ linear method	per µg /m3	4.4x10-6	Inhalation
552	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LMS method	per µg /m3	8.8x10-6	Inhalation
553	Vinyl chloride	75-01-4	Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules	LED 10/ linear method	per µg /m3	8.8x10-6	Inhalation
554	Warfarin	81-81-2	Not Assessed under the IRIS program.
555	White phosphorus	7723-14-0	Not Assessed under the IRIS program.
556	Xylenes	1330-20-7	Not Assessed under the IRIS program.
557	Zinc and Compounds	7440-66-6	Not Assessed under the IRIS program.
558	Zinc cyanide	557-21-1	Not Assessed under the IRIS program.
559	Zinc phosphide	1314-84-7	Not Assessed under the IRIS program.
560	Zineb	12122-67-7	Not Assessed under the IRIS program.

Rationale

• IRIS

See also

• IRIS

Related files

<mfanonymousfilelist></mfanonymousfilelist>